{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:09:55Z","timestamp":1788988195790,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003792","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun and Bertil Stohnes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Foundation for Old Maids","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"King Gustaf V and Queen Victoria's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-03524"],"award-info":[{"award-number":["2021-03524"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-02963"],"award-info":[{"award-number":["2024-02963"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-01083"],"award-info":[{"award-number":["2021-01083"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2025-02940"],"award-info":[{"award-number":["2025-02940"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.neurot.2026.e00949","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:35:26Z","timestamp":1782304526000},"page":"e00949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Elin","family":"Wik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia D.","family":"Dahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Julku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Michno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Sehlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00949_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","article-title":"Sensitive ELISA detection of amyloid-beta protofibrils in biological samples","volume":"103","author":"Englund","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2026.e00949_bib2","doi-asserted-by":"crossref","first-page":"22364","DOI":"10.1074\/jbc.272.35.22364","article-title":"Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate","volume":"272","author":"Walsh","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2026.e00949_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032014","article-title":"Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation","volume":"7","author":"Sehlin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00949_bib4","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1111\/j.1742-4658.2006.05263.x","article-title":"Physiochemical characterization of the Alzheimer's disease-related peptides Ab 1-42Arctic and Ab 1-42wt","volume":"273","author":"Johansson","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.neurot.2026.e00949_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2026.e00949_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00949_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54779-w","article-title":"Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's disease","volume":"15","author":"Balig\u00e1cs","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00949_bib8","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","article-title":"Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer's disease","volume":"31","author":"van Olst","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e00949_bib9","doi-asserted-by":"crossref","first-page":"eads3204","DOI":"10.1126\/science.ads3204","article-title":"Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA","volume":"389","author":"Pizzo","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.neurot.2026.e00949_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100214","article-title":"Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease","volume":"12","author":"Sehlin","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2026.e00949_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","article-title":"Efficient clearance of Abeta protofibrils in AbetaPP-transgenic mice treated with a brain-penetrating bifunctional antibody","volume":"10","author":"Syvanen","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2026.e00949_bib12","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00949_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer's disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.neurot.2026.e00949_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2026.e00949_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-022-00398-w","article-title":"Brain pharmacokinetics of mono- and bispecific amyloid-beta antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis","volume":"19","author":"Julku","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neurot.2026.e00949_bib16","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1021\/acsptsci.5c00359","article-title":"Fluorine-18 ImmunoPET imaging of antibody brain kinetics and amyloid-beta pathology","volume":"8","author":"Schlein","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.neurot.2026.e00949_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071412","article-title":"Reduction of \u03b1SYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody","volume":"14","author":"Roshanbin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2026.e00949_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108985","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","volume":"208","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2026.e00949_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.neurot.2026.e00949_bib20","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1007\/s00259-025-07358-0","article-title":"PET imaging of TREM2 in amyloid-beta induced neuroinflammation","volume":"52","author":"Dahl\u00e9n","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.neurot.2026.e00949_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/bj0890114","article-title":"The preparation of I-131-Labelled human growth hormone of high specific radioactivity","volume":"89","author":"Greenwood","year":"1963","journal-title":"Biochem J"},{"key":"10.1016\/j.neurot.2026.e00949_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neurobiolaging.2004.12.007","article-title":"The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice","volume":"27","author":"Lord","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurot.2026.e00949_bib23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.neurobiolaging.2007.11.022","article-title":"A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice","volume":"30","author":"Philipson","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurot.2026.e00949_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/19420862.2018.1473910","article-title":"Antibody pharmacokinetics in rat brain determined using microdialysis","volume":"10","author":"Chang","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.neurot.2026.e00949_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1645952","article-title":"Key considerations for ELISA-based quantification of diverse amyloid beta forms in murine brain homogenates","volume":"19","author":"Metzendorf","year":"2025","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2026.e00949_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11307-021-01591-3","article-title":"Pinpointing brain TREM2 levels in two mouse models of alzheimer's disease","volume":"23","author":"Meier","year":"2021","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.neurot.2026.e00949_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1152\/physrev.00027.2007","article-title":"Diffusion in brain extracellular space","volume":"88","author":"Sykov\u00e1","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.neurot.2026.e00949_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.neuron.2023.04.007","article-title":"Abundant A\u03b2 fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains","volume":"111","author":"Stern","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e00949_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6184","article-title":"The Uppsala APP deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid beta fibril formation","volume":"13","author":"Pagnon de la Vega","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurot.2026.e00949_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-022-01283-y","article-title":"A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in alzheimer's disease mice","author":"Rofo","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e00949_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-023-01236-3","article-title":"Long-term effects of immunotherapy with a brain penetrating A\u03b2 antibody in a mouse model of Alzheimer's disease","volume":"15","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2026.e00949_bib32","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/jnc.16127","article-title":"Antibody engagement with amyloid-beta does not inhibit [ 11 C]PiB binding for PET imaging","volume":"168","author":"Xiong","year":"2024","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2026.e00949_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41593-025-02125-8","article-title":"The Alzheimer's therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia","volume":"29","author":"Albertini","year":"2026","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2026.e00949_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13024-025-00878-1","article-title":"Early intervention anti-A\u03b2 immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques","volume":"20","author":"de Weerd","year":"2025","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2026.e00949_bib35","article-title":"Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies","volume":"395","author":"Dahl\u00e9n","year":"2025","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e00949_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-024-01734-x","article-title":"Altered amyloid-\u03b2 structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion","volume":"12","author":"Pagnon de la Vega","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e00949_bib37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","article-title":"Anti-inflammatory clearance of amyloid-\u03b2 by a chimeric Gas6 fusion protein","volume":"28","author":"Jung","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e00949_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1874121","article-title":"Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis","volume":"13","author":"Chang","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.neurot.2026.e00949_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1918819","article-title":"Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion","volume":"13","author":"Le Prieult","year":"2021","journal-title":"mAbs"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:37:00Z","timestamp":1788986220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1878747926001194"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00949","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00949"}}